Brooks Laboratories Ltd (BROOKS) — shareholding pattern, promoter holding, financials and share price
About Brooks Laboratories Ltd (BROOKS)
Brooks Laboratories Ltd operates in the Pharmaceuticals industry, within the Healthcare sector. It trades on the NSE as BROOKS and on the BSE under scrip code 533543. Its ISIN is INE650L01011.
Incorporated in 2002, Brooks Laboratories Ltd is a pharmaceutical company working on contract basis catering to the critical care segment [1]
Brooks Laboratories Limited is a pharmaceutical manufacturing company specializing in the production of injectables, tablets, and dry syrups. It operates on a contract basis with major pharmaceutical clients.
The company has two cGMP compliant manufacturing plants located in Baddi, Himachal Pradesh, and Vadodara, Gujarat. The Vadodara facility is notably approved by the European Medicine Agency, underlining its international quality standards.
Listed peers in Pharmaceuticals: Nectar Lifescience Ltd, Kerala Ayurveda Ltd, Coral Laboratories Ltd, Syschem (India) Ltd, Gujarat Inject (Kerala) Ltd, Achyut Healthcare Ltd.
Valuation & Returns
10 Jul 2026At ₹71.8 a share on 10 Jul 2026, Brooks Laboratories Ltd (BROOKS) was valued at a price-to-earnings ratio of 8.6x against an industry P/E of 36.41x and a price-to-book of 2.16x on a book value of ₹33.3 per share as of Mar 2025. Solomo computes return on equity of 25.05% and return on capital employed of 24.04% from filed results. Earnings ratios use consolidated results for the twelve months Jun 2025 to Mar 2026.
- P/E
- 8.6x
- Industry P/E
- 36.41x
- P/B
- 2.16x
- EPS (TTM)
- ₹8.34
- Book value / share
- ₹33.3
- ROE
- 25.05%
- ROCE
- 24.04%
- ROA
- 19.87%
- Debt / equity
- 0.08x
- Dividend yield
- 0%
- EBITDA margin
- 31.49%
- 52-week range
- ₹36.9 – ₹165.95
Ratios are computed from filed results and the last recorded price. Not investment advice.
Financial Performance
Mar 2026In the year ended Mar 2026, Brooks Laboratories Ltd (BROOKS) reported revenue of ₹86 crore, net profit of ₹25 crore and earnings per share of ₹8.34. That compares with revenue of ₹83 crore and net profit of ₹-10 crore in Mar 2025. Figures are consolidated, as filed with the exchanges.
In the quarter ended Mar 2026, revenue was ₹20.21 crore and net profit ₹1.52 crore (consolidated).
| Metric | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Revenue (₹ cr) | 91 | 63 | 79 | 83 | 86 |
| Net profit (₹ cr) | -19 | -31 | -20 | -10 | 25 |
| EPS (₹) | -4.31 | -7.97 | -7.46 | -3.38 | 8.34 |
| Measure | 10Y | 5Y | 3Y | 1Y |
|---|---|---|---|---|
| Sales growth | 0.35% | 3.45% | 2.36% | 3.86% |
| Profit growth | -12.95% | - | 66.10% | 49.11% |
| Stock price CAGR | -3% | -5% | -4% | -56% |
Ownership Summary
Jun 2026As of Jun 2026, promoters hold 52.62% of Brooks Laboratories Ltd (BROOKS) (unchanged from the previous quarter), foreign institutional investors (FII) hold 0% and domestic institutional investors (DII) hold 10.38%. Market capitalisation was ₹212 crore on 10 Jul 2026. Shareholding is filed quarterly with BSE and NSE; Solomo carries every filing back to Sep 2011.
Largest disclosed public shareholders in Jun 2026: Quant Mutual Fund - Quant Business Cycle Fund 9.9%, Saumik Ketankumar Doshi 1.2%, One Up Financial Consultants Pvt Ltd 1.02%. Only stakes above the 1% disclosure threshold are named in filings.
| Quarter | Promoter | Pledged | FII | DII | Public |
|---|---|---|---|---|---|
| Jun 2026 | 52.62% | - | 0% | 10.38% | 47.38% |
| Mar 2026 | 52.62% | - | 0.17% | 10.38% | 47.38% |
| Dec 2025 | 52.62% | - | 0.09% | 10.38% | 47.38% |
| Sep 2025 | 52.62% | - | 0.01% | 10.38% | 47.38% |
| Jun 2025 | 52.62% | - | 0% | 10.38% | 47.38% |
| Mar 2025 | 52.62% | - | 0.05% | 10.38% | 47.38% |
| Dec 2024 | 59.06% | - | 0.01% | 3.86% | 40.94% |
| Sep 2024 | 63.59% | - | 0.02% | 3.86% | 36.41% |